Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Dermatologic reactions linked to GLP-1 therapy are gaining attention as the use of glucagon-like peptide-1 receptor agonists continues to expand in diabetes and obesity care. While injection-site irritation is well recognized, clinicians are increasingly observing broader skin changes in patients treated with semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and tirzepatide …
Read More »GLP-1s and Dermatologic Reactions: Beyond Injection-Site Effects
